Urzac (+Pridinol)

Quick links

Choose a section

Quick links to important sections

Advertisements

Urzac (+Pridinol)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Urzac (+Pridinol)

Property Description
Active Ingredients Meloxicam, Pridinol mesilate
Form Oral tablet (Fixed-dose combination)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID) and Centrally Acting Muscle Relaxant
Common Therapeutic Purpose Relief of pain associated with inflammation and muscle contractures
Origin Synthetic chemical compounds

1. Classification and Composition: What Type of Medicine is Urzac (+Pridinol)?

Urzac (+Pridinol) is a fixed-dose combination product prepared as an oral tablet that delivers two distinct pharmacological actions simultaneously. The preparation contains two synthetic active ingredients: Meloxicam and Pridinol mesilate. Meloxicam is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) of the oxicam class. Pridinol mesilate belongs to the class of Centrally Acting Muscle Relaxants. This dual-component structure results in a specialized pharmaceutical type clinically recognized for synergistic efficacy in musculoskeletal pain management, a formulation strategy often chosen for enhanced therapeutic breadth.

2. Dual Action: How Does Urzac Address Pain and Muscle Spasm?

The general therapeutic purpose of Urzac is to provide comprehensive relief for musculoskeletal discomfort by targeting its inflammatory and spastic elements. The Meloxicam component works to reduce the body's inflammatory response, mitigating the swelling and localized pain, which is the established function of this NSAID component. This is strategically combined with the Pridinol mesilate component, which acts on the central nervous system to reduce muscle rigidity and alleviate involuntary tension or muscular contractures. This strategic dual action is employed to offer a more foundational response to pain syndromes, making it suitable for scenarios like acute low back pain where stiffness significantly compounds the overall discomfort.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Urzac (+Pridinol)?

Possible Side Effects and Safety Information for Urzac (Pridinol)

This information is based on official government regulatory documents (e.g., Summary of Product Characteristics, Prescribing Information) and describes the officially documented risks associated with Urzac (Pridinol).

Frequency-Classified Adverse Reactions

The side effects of Urzac are classified by regulatory agencies based on their frequency of occurrence, primarily reflecting the drug's anticholinergic properties:

  • Common (may affect up to 1 in 10 people): Includes mild, expected effects such as Headache, Dizziness, and Dry Mouth.
  • Uncommon to Rare: Less frequent effects may involve vision disturbances (e.g., accommodation disorders), nausea, and increased heart rate (tachycardia).

System-Organ-Class (SOC) Safety Groups

Regulatory documents group adverse reactions by the body system affected. Common SOC categories documented for Pridinol include Nervous System Disorders, Gastrointestinal Disorders, and Eye Disorders.

Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions: Rare but clinically significant reactions that are formally documented include Severe Hypersensitivity Reactions (e.g., anaphylaxis) and central nervous system effects such as Confusion or Delirium, particularly in sensitive patient populations.

Safety Restrictions (Contraindications): Urzac is strictly prohibited for use in specific pre-existing conditions, which are documented as Contraindications in regulatory labeling. These include:

  • Angle-closure glaucoma
  • Prostatic hypertrophy with residual urine formation
  • Tachyarrhythmia

Population-Specific Safety Considerations

Official labels contain specific statements for vulnerable groups:

  • Elderly Use: Caution is advised due to increased sensitivity to anticholinergic effects.
  • Pregnancy and Lactation: Use is generally not recommended unless the treating clinician determines it is clearly necessary, due to limited data.
  • Impaired Organ Function: Use is restricted or not recommended in cases of severe renal or hepatic impairment.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required in the event of any suspected overdose or accidental ingestion of Urzac (+Pridinol).

The documented symptoms of overdose are related to the actions of the two active components. Manifestations tied to the Meloxicam component are generally reversible and may include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Symptoms related to the Pridinol mesilate component include those typical for anticholinergics. Individuals who suspect an overdose and experience signs of an anaphylactic reaction must seek emergency help immediately.

A severe overdose is documented to carry the risk of critical outcomes, potentially affecting multiple physiological systems. These severe manifestations may include acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest. Elderly patients or those with a history of gastrointestinal bleeding are noted as being at a greater risk for serious gastrointestinal events following an overdose.

Management relies on symptomatic and supportive care. While no specific antidote is known for the Meloxicam component, the official labeling describes the use of intravenous physostigmine salicylate for severe Pridinol mesilate-related symptoms. Procedural support includes the administration of activated charcoal and Cholestyramine to accelerate clearance.

Advertisements

Therapeutic Uses of Urzac (+Pridinol)

What Urzac (+Pridinol) Treats: Main Uses and Benefits

The therapeutic application of Urzac (+Pridinol), a fixed-dose combination, is commonly used to help with conditions where symptoms related to physical discomfort stem from both inflammatory or irritative states and symptoms of increased muscular activity. This approach is generally used for managing symptom clusters that create noticeable physiological strain and interfere with daily functioning.

The association is considered relevant for treating muscular contractures and low back pain.


Core Symptomatic Focus

The medication is commonly used to provide symptomatic relief in conditions characterized by localized pain and inflammation within the musculoskeletal system. It is applied across therapeutic domains involving heightened symptoms such as lumbago and flare-ups of conditions like osteoarthritis and rheumatoid arthritis when accompanied by significant muscle tension. This strategic focus provides support that helps ease the overall symptom burden.

The combination is relevant in contexts marked by increased discomfort, specifically in conditions where symptoms are driven by both inflammation and spasms. This strategy supports the patient during difficult episodes by easing overall distress. Applied during phases of increased distress, this combination may assist with maintaining functional stability when symptoms become temporarily overwhelming.

Quick Fact: Relief for Pain, Inflammation, and Muscle Spasm

Advertisements

Eligibility and Restrictions for Use

Urzac (+Pridinol) is primarily established for use in adults (18 years and older). Official regulatory documents define clear eligibility and non-eligibility rules, often reflecting the restrictive nature of its NSAID component (Meloxicam) and the properties of its muscle relaxant component (Pridinol mesilate).


Absolute Contraindications

Use of this medication is formally prohibited in populations documented as:

  • Patients with known hypersensitivity to Meloxicam, Pridinol mesilate, aspirin, or other NSAIDs.
  • Individuals with active gastrointestinal ulceration or hemorrhage or a history of recurrent peptic ulcers.
  • Patients with severe, non-dialyzed renal failure (CrCl < 25 mL/min), severe heart failure, or severe hepatic impairment.
  • Patients diagnosed with narrow-angle glaucoma, prostate hypertrophy, or gastrointestinal obstructions.
  • Women in the first trimester and the third trimester of pregnancy. The medicine is not established for general use in children and adolescents under 16 years of age.

Populations Requiring Caution or Restriction

  • Older adults (65+) are considered a population at higher risk for serious gastrointestinal and renal events, necessitating cautious use.
  • Patients with end-stage renal failure on hemodialysis may use the medicine only under strict dosage restriction.
  • Use is generally not recommended for women who are attempting to conceive or while breastfeeding.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Urzac, a fixed-dose combination containing Meloxicam (NSAID) and Pridinol mesilate (Centrally Acting Muscle Relaxant), based strictly on regulatory sources.

Contraindicated and High-Risk Combinations

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors and analgesic doses of aspirin, is not generally recommended due to an increased risk of serious gastrointestinal events. Meloxicam is formally contraindicated for the treatment of peri-operative pain in the context of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure-Modifying Interactions

Interacting Substance/Class Official Interaction Description
Anticoagulants/Antiplatelet Agents Increased risk of bleeding when combined with agents that interfere with hemostasis (e.g., Warfarin, SSRIs).
Antihypertensives/Diuretics May officially diminish the blood pressure-lowering and natriuretic effects of drugs like ACE inhibitors, ARBs, and Furosemide.
Lithium or Methotrexate Co-administration leads to documented increased plasma concentrations and potential toxicity of Lithium and Methotrexate, respectively.
Anticholinergic Agents Pridinol mesilate may increase the pharmacodynamic response of other medicines in the anticholinergic group.

Co-administration with certain blood pressure medications (ACE inhibitors, ARBs) carries a heightened risk of deterioration of renal function in high-risk patients, such as the elderly or volume-depleted individuals, as specified in regulatory documentation. Use with alcohol may increase the risk of serious gastrointestinal bleeding.

Advertisements

Mechanism of Action

How Urzac (+Pridinol) Works

Urzac, containing Pridinol, exerts its pharmacodynamic effect through the modulation of key receptor- and enzyme-mediated signaling pathways within the central and peripheral nervous systems. Pridinol acts primarily as an anticholinergic agent by engaging and mediating the activity of muscarinic acetylcholine receptors (mAChRs).

This specific receptor interaction initiates signaling sequences that interfere with the normal transmission of nerve impulses involved in regulating involuntary muscle contraction and autonomic processes. By occupying these receptor sites, Pridinol modifies the early molecular steps that govern downstream excitation. This results in the suppression of excessive cholinergic activity within the targeted pathways, leading to the adjustment of signaling activity. The consequence is a defined system-level physiological modulation involving the attenuation of heightened neuromuscular and autonomic responsiveness, thereby influencing systemic physiological tone.

Advertisements

Dosage and Administration Information

How to Use Urzac (+Pridinol)

This section describes the high-level principles for the use of Urzac (+Pridinol), a fixed-dose oral tablet combination of Meloxicam and Pridinol mesilate.


Official Administration Guidelines

Administration of this medicine is restricted to the oral route via the tablet form. The entire daily prescribed amount must be taken as a single dose once per day.

Usage Constraint Requirement or Range
Standard Daily Dose Typically begins at the 7.5 mg Meloxicam equivalent, adjustable based on need.
Maximum Daily Limit The dose must not exceed the 15 mg Meloxicam equivalent.
Administration Timing Should be swallowed with water or other liquid. May be taken with or without food.
Duration of Use Use the lowest effective dose for the shortest duration consistent with treatment goals, requiring periodic re-evaluation of necessity.

Population-Specific Use

For older adults or patients identified as having an increased risk, treatment is usually initiated with the lower 7.5 mg equivalent dose. A critical dosing restriction applies to patients with severe renal impairment who are undergoing hemodialysis, for whom the dose equivalent must also not exceed 7.5 mg per day. Dose modifications are typically not required for mild to moderate hepatic or renal impairment. This structured approach ensures adherence to established limits and procedural constraints.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urzac (+Pridinol)


Evidence Supporting the Fixed-Dose Combination in Muscular Contractures and Low Back Pain

Research examining the fixed-dose combination of Meloxicam and Pridinol mesilate explored outcomes related to physical discomfort, particularly in conditions associated with acute or disruptive episodes like low back pain and muscle contractures. Limited, specific trials examined patient-reported outcomes describing perceived discomfort and outcomes capturing phases of heightened symptom activity over defined time intervals.

Evidence is limited for the fixed-dose combination product specifically. Comparative evidence is lacking for studies that directly test the Urzac combination against a placebo or its individual components given separately. The research highlights that long-term effects are not fully established, as the majority of available data focuses on short-term treatment periods.


Foundational Evidence for the Muscle Relaxant Component: Pridinol

The muscle relaxant component, Pridinol mesilate, was studied for outcomes related to systemic or functional imbalance in patients with acute muscle pain. The body of evidence includes systematic reviews that consolidate findings from multiple double-blind, controlled trials. Additionally, large observational studies was evaluated in observational settings evaluating daily-life functioning in adult patients. Some trials described patterns where the use of Pridinol mesilate was associated with changes in the concurrent intake of other pain relief medications.


Research Context: Evidence for the Anti-Inflammatory Component: Meloxicam

The anti-inflammatory component, Meloxicam, was studied for a wide range of inflammatory conditions, and is supported by a large volume of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. This extensive research was evaluated in patients with conditions characterized by fluctuating or episodic manifestations like Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

It is important to understand that this research is not specific to the fixed-dose combination of Urzac. The trials focused solely on the effects of Meloxicam monotherapy, evaluating the outcomes linked to inflammatory or irritative states rather than the combined influence of inflammation and muscle spasm.


Key Evidence Gaps and Areas of Scientific Uncertainty

The most significant gap is the limited comparative evidence specific to the Urzac combination itself. While the individual components are well-studied, there is a lack of high-quality RCTs to explore the role of the fixed-dose product versus using the two ingredients separately. The follow-up durations were limited in many of the core trials, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Meloxicam: NSAID of the oxicam class
  2. Efficacy and tolerability of pridinol mesylate in acute muscle pain: a meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Urzac (+Pridinol) (FAQ)


Q: How quickly does Urzac usually start working after taking it?

According to official product information, the Meloxicam component of Urzac typically reaches its highest levels in the bloodstream approximately 4 to 10 hours after oral administration. Achievement of full anti-inflammatory benefits for certain conditions may take several days to a couple of weeks of consistent administration.


Q: How long do the effects of one dose of Urzac last?

The Meloxicam component of Urzac has a half-life of approximately 15 to 20 hours, which is the pharmacological basis for its once-daily dosing. This duration reflects how long the body takes to reduce the amount of the drug by half.


Q: What are the long-term effects of taking Urzac regularly?

Regulatory warnings emphasize that the medication should be used at the lowest effective dose for the shortest duration necessary. Official information indicates that the risk of serious side effects, particularly those affecting the cardiovascular system and the stomach or intestines, may increase with the duration of use.


Q: Can Urzac cause stomach upset or nausea?

Yes, nausea is documented as an Uncommon to Rare side effect. Additionally, the Meloxicam component is associated with common gastrointestinal symptoms like indigestion (dyspepsia) and diarrhea. These potential effects are noted in the product information.


Q: Can Urzac be taken on an empty stomach?

Official administration guidelines state that Urzac tablets should be swallowed with water or another liquid, and they may be taken with or without food.


Q: What is the mechanism by which Pridinol acts in the body?

Pridinol, the muscle relaxant in Urzac, is classified as an anticholinergic agent. It works by acting on specific receptors in the central and peripheral nervous systems, helping to suppress excessive nerve activity that causes muscle stiffness and spasms.


Q: Do people take Urzac every day, or just as needed?

The medication is designed for administration as a single dose once per day. Official guidelines stress that use should be for the shortest duration consistent with treatment goals, and the necessity of continuing the medicine requires periodic re-evaluation.


Q: Can Urzac affect my ability to drive or operate machinery?

Yes, Urzac may affect your ability to drive or use machinery. Common side effects include dizziness and headache, and less common effects may involve vision disturbances. Individuals should observe how the medication affects them before performing activities that require concentration, such as driving or operating machinery.


Q: Are there any serious side effects of Urzac that I should watch out for?

Rare but serious risks are documented, including severe hypersensitivity reactions (like anaphylaxis) and central nervous system effects such as confusion or delirium. Additionally, the NSAID component (Meloxicam) carries specific regulatory warnings regarding the potential for serious gastrointestinal bleeding and cardiovascular events.


Q: Is there a generic version of Urzac available?

The anti-inflammatory component, Meloxicam, is widely available generically. The fixed-dose combination product containing both Meloxicam and Pridinol mesilate may be marketed under various brand names in different countries.


Q: Is Urzac ever prescribed to children or teenagers?

Urzac is generally restricted to use in adults 18 years and older. According to regulatory labeling, it is not established for general use in children and adolescents under 16 years of age.


Q: Does Urzac affect my mood or cause anxiety?

The drug's official label notes rare, serious side effects related to the central nervous system, including confusion or delirium. These effects are particularly noted in sensitive patient populations.


Q: What medical research supports the use of Urzac for muscle stiffness?

Studies have explored the combination product's use for acute conditions like low back pain and muscle contractures. However, official information points out that the body of research for the fixed-dose combination specifically is limited, and there is a lack of studies directly comparing it to its individual components.


Q: Are there any dietary restrictions I need to follow while taking Urzac?

The primary interaction warning is that using Urzac with alcohol may increase the risk of serious gastrointestinal bleeding. No other major dietary restrictions are explicitly noted in the regulatory warnings.


Q: Can taking Urzac affect the results of other lab tests?

Yes, Urzac can affect the levels of other medicines in your blood. For instance, co-administration with Lithium or Methotrexate is documented to lead to increased plasma concentrations and potential toxicity of those drugs, which requires careful monitoring.


Q: What is the maximum duration people typically use Urzac for?

Official regulatory guidelines specify that the medicine must be used for the shortest duration consistent with treatment goals. Ongoing use requires periodic re-evaluation by a healthcare provider to determine if the medication is still necessary.


Q: Are there any warnings about sun exposure while on Urzac?

The NSAID component (Meloxicam) may increase your skin's sensitivity to ultraviolet (UV) rays from sources like the sun or tanning lamps. Official information advises patients to take precautions to limit exposure to UV rays while using this medication.


Q: Why is Urzac sometimes called a 'centrally acting' drug?

Urzac is sometimes called a centrally acting drug because its muscle relaxant component, Pridinol mesilate, works by modulating signaling pathways within the central nervous system (CNS), rather than acting directly on the muscles themselves.


Q: Can men and women use Urzac equally, or are there gender-specific warnings?

Use is generally restricted for women who are pregnant, breastfeeding, or attempting to conceive. There are no specific warnings or restrictions for men noted in the regulatory documents.


Q: Are there studies about Urzac's effectiveness in sports-related injuries?

The available research for the fixed-dose combination product focuses on conditions like low back pain and muscle contractures. Studies are not specifically noted in regulatory summaries regarding general sports injuries.


Q: Is it normal for Urzac to make me feel more relaxed?

While the drug is primarily designed to reduce muscle tension, its Common side effects include Dizziness, which may be perceived as a state of relaxation. Its main therapeutic action is to relieve muscle rigidity and spasms.


Q: What are the active metabolites of Urzac once it's processed by the body?

The Meloxicam component is metabolized (processed) by the body into four main metabolites, which are considered biologically inactive. Information about the inactive nature of the Pridinol metabolites is typically available in the full prescribing information.


Q: Is the effect of Urzac immediately noticeable, or is it cumulative?

The drug reaches its peak concentration in the blood within hours of a single dose. However, official information suggests that full anti-inflammatory benefits for chronic conditions may require consistent administration for several days to a couple of weeks to achieve its overall cumulative effect.

Advertisements

How should Urzac (+Pridinol) be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Urzac (+Pridinol) oral tablets are based on mandated regulatory guidelines for its active ingredients, ensuring product stability and public safety.

Storage Conditions

Requirement Specifics
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep the tablets in the original container, tightly closed, and protected from moisture and light.
Child Safety Keep out of the sight and reach of children and pets at all times.
Stability Do not use the medicine past the expiration date printed on the packaging.

Disposal Instructions

Unused or expired tablets should be disposed of by following official governmental guidelines, preferably utilizing a drug take-back program. The medicine must not be flushed down the toilet or poured into wastewater systems. If a take-back program is unavailable, tablets should be mixed with an undesirable substance (e.g., dirt) and sealed for disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urzac (+Pridinol) found in:

A-Z Index: